The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
https://www.tradingview.com/x/Eyqp3rAk/
forgot to add the chart. sunshine and beers dont mix!
potential bounce/ support at the 112-122p. with rising trend channel. drawn two channels as uncertain which will hold. but should be good for support. hopefully hits the 122p support and then rises but chart still looking healthy in current consolidationn period from recent high at 144p. obviously chart is based on no news coming out
thank god!!! squeaky bum fore a bit. but glad they have pulled the rabbit out the hat. or beginning to. all chips now lie with pacificorp burn trial. a success and we can forget about the years of crap! if it isnt then i wouldnt like to see the effect on the sp.
lets have a nice reaction from the market today please.
true miavoce and one would think the next 510k submission after this current de novo for metastatic breast cancer would be for ovarian cancer with all the data supplied by the current trails (which should be by end of the year) you would think there would be enough data to be supplied along with the 510k submission. other cancer related submissions would need the trails along with it to prove the parsortix works with that related cancer cells. to be honest i dont know what data is needed for each 510k submission and how in depth this data needs to be. but happy for AGL to venture into any kind of cancer expanding its IP.
thanks for the link diversified. more or less the same presentation weve seen a couple of times over the past few weeks but the Q & A at the end was interesting.
2:37... "we will become a very very large company or owned by a large company" if that isnt a reason to keep invested i dont know what is.
some are not giving AGL enough credit on what parsortix is and how its going to be huge!
ben. only deadline thats been set is from the HKex. which is sept 2022. without news CNEL will be delisted. im hoping we dont have to wait a year for news. you would of thought this would have to rectified as soon as possible. but this is CNEL at the end of the day!
ward the main reason stocks drop is the smart money has already bought into the stock. so say a drug company has had a drug approved theres usually a run up in price from the lows where the big money and ii money get in. they either hold longterm or sell/ de-risk when news comes out. same with different sectors like oil/gas. theres a run up pre drills etc. usually its the new investors that gets spiked on these types of binary plays either hit or miss. but once AGL gets FDA approval i personally think its the start of the growth. of course there will be selling along the way as everyone has different exit targets and rightly so. some bought in at 40p. others last week. so all viewing their investment differently. it may spike on FDA news then consolidate but should settle then progress up throughout the year. it all depends how much return you want and how long you want to wait.
once FDA approval has been granted i have no issues with funding since the investment will be basically be derisked. its already derisked when the first pharma contract was signed so moved away from a binary play. so when FDA os granted i view this is a total derisked investment (going on my avg sp and projected future sp) if they have a placement to fund growth this is only a bonus as it will fast track all future orders of parsprtix and get deals done meeting expected high demand. it will only be to fund growth rather than line the BODs pocket which has never been the case here :)
i think we'll be pleasantly surprised how many orders/ contracts/ partnerships gey signed soon after FDA approval :)
champagnecharlie what i was meaning was AN mentioned it would go to shareholders to vote on a buyout but he mentioned that he and the major shareholders have put across that they want to grow the business instead of looking at a buyout. when the question came along he didnt hesitate saying there could be an option at a buy out at that price he bascailly said they want to grow the business and for my opinion that would be upwards £13.
i won't post much on that figure as its many multiples of todays sp and would take years to achieve this kind of figure. im more than happy to let the company do its thing and the sp will take care of itself
the main issue with aim market is its full of 'jam tomorrow' stocks and CEOs who pump their for own personal benefit or usually to let the big deep pockets forward sell an up and coming placement. this has had an impact on pis trading patterns where a high majority of aim traders/investors view 2 weeks as a long wait. they always want to make a fast buck as fast as possible then join onto the next pump luring inexperienced pis into crap stock as the bbs full of mindless ramping or even deramping. people overlook the gems thats out there that takes years to come to come good. but when they do its usually strength after strength moving away from the cesspit of aim market and move towards a bigger market like FTSE or in our case NASDAQ.
i agree there will be a drift but like you say the sp could hold up once we enter into the H2 and FDA info have been submitted. news could drop anytime so people will most likely stick around, or even the majority supporting a higher sp.
some of the long termers on this board have been here years, some close to a decade. they seen the vision in parsortix back then and believed in AN. maybe most would of thought they would of been at this stage sooner but over the years the information coming out from AGL has been outstanding and i personally think AN has done a superb job making the cash work well. compared the the average aim listed stock there is a little amount of shares out there and over the years have been limited placings. each year there seems to be more markets AGL/parsortix can be used and the overall market for parsprtix is mind boggling. if they can even get a fraction of this market it will make a huge difference in revenue to AGL. let alone becoming the market leader/ gold standard/ top dog!
AN was throwing out a £13 buyout figure in last nights presentation. do you think he and the big ii's behind agl are worried about a drift in sp? only way its going is up over the years. ride out the bumps along the way and AGL has the ability to make you a serious return on investments.
once in a life time stock springs to mind. all the super giants of the pharma world start off small. theres no reason why AGL cant sit at the same table over the next decade.
"There is an urgent need for targeted treatment options to improve patient outcomes."
and how do you select the correct treatment? early and correct diagnose using the parsortix device.
and to think they mass heard havent got behind AGL yet is crazy.(pi's not company related)
i think after world domination by parsortix theyre going to have a clinic near every major cancer treatment locations/cities around the world! every pieces of news that comes out only strengthens AGLs case and shows the dire need for their product just now!
thats a nice surprise to read, to have not one plant theyve been busy building but a second one that should be operational in a few weeks. that could be a big boost if they can get to full production and splitting profits 50/50.
some would say excellent news. lets see how the market reacts. lets get the permits sorted and go full pelt at those pellets
on my charts im seeing a possible breather from 150-155p. there is heavy buying of late so think theres a nothing push to end the week on a high. then we may consolidate (without newsflow) but chart is still bullish. minus the technically overbought region.